Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK’s Tanzeum Launch Marks The Big Pharma’s Return To Diabetes

This article was originally published in The Pink Sheet Daily

Executive Summary

GSK expects Tanzeum will be one of its “core big six” drugs despite the fact that it is the fourth GLP-1 to market. VP-General Medicines Cheryl MacDiarmid discussed GSK’s return to diabetes in an interview.

You may also be interested in...



10 Drug Launch Flops Of The Decade

The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.

J&J Prepares For US Sirukumab Launch After Regaining Rights From GSK

GSK returned US rights to the IL-6 blocker to J&J as it prioritizes its pharma portfolio under the leadership of new CEO Walmsley.

Changing Face Of ‘Me Too’ Drugs On Display In 2014 NME Approvals

As the era of the primary care blockbusters waned, pharma R&D shifted toward less price-sensitive specialty fields. Now successful specialty drug development is producing its own sort of follow-on agents, and payers are pushing back. Even oncology is not immune.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS077494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel